ARTICLE | Strategy
XO1's hit men
How J&J's role in advising XO1 triggered takeout of anticoagulant play
March 30, 2015 7:00 AM UTC
Johnson & Johnson's hands-on role in the development of XO1 Ltd.'s ichorcumab and knowledge of the anticoagulant space convinced the pharma the time was right to acquire the preclinical biotech.
On March 19, J&J's Janssen Pharmaceuticals Inc. unit said it acquired the Index portfolio company for an undisclosed sum to gain its sole asset, ichorcumab. The mAb is a synthetic version of an antibody discovered in a patient that could prevent thrombosis without increasing risk of bleeding, a side effect of marketed anticoagulants. ...